Header

UZH-Logo

Maintenance Infos

Emerging immunotargets and immunotherapies in prostate cancer


Montironi, Rodolfo; Santoni, Matteo; Sotte, Valeria; Cheng, Liang; Lopez-Beltran, Antonio; Massari, Francesco; Matrana, Marc R; Moch, Holger; Berardi, Rossana; Scarpelli, Marina (2016). Emerging immunotargets and immunotherapies in prostate cancer. Current Drug Targets, 17(7):777-782.

Abstract

Innate and adaptive immunity are both involved in prostate cancer (PCa) carcinogenesis and progression. On this scenario, several immunotherapeutic approaches have been proposed and are presently under extensive investigation in PCa patients. Among emerging immune targets, immune checkpoint inhibitors such as anti-cytotoxic T-lymphocyteassociated protein 4 (CTLA-4), anti-Programmed death-1 (PD-1) and anti-Programmed death-ligand-1 (PD-L1) agents seem to represent the most promising candidate for these patients, together with oncolytic viruses and vaccines, used alone or in combined strategies. In this review, we focused on emerging immunotherapeutic approaches in patients with PCa, showing the rational for their association with current standard therapies including anti-androgen agents, chemo- or radiation therapy.

Abstract

Innate and adaptive immunity are both involved in prostate cancer (PCa) carcinogenesis and progression. On this scenario, several immunotherapeutic approaches have been proposed and are presently under extensive investigation in PCa patients. Among emerging immune targets, immune checkpoint inhibitors such as anti-cytotoxic T-lymphocyteassociated protein 4 (CTLA-4), anti-Programmed death-1 (PD-1) and anti-Programmed death-ligand-1 (PD-L1) agents seem to represent the most promising candidate for these patients, together with oncolytic viruses and vaccines, used alone or in combined strategies. In this review, we focused on emerging immunotherapeutic approaches in patients with PCa, showing the rational for their association with current standard therapies including anti-androgen agents, chemo- or radiation therapy.

Statistics

Citations

5 citations in Web of Science®
3 citations in Scopus®
Google Scholar™

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Institute of Pathology and Molecular Pathology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2016
Deposited On:11 May 2016 19:12
Last Modified:08 Dec 2017 19:29
Publisher:Bentham Science Publishers Ltd.
ISSN:1389-4501
Publisher DOI:https://doi.org/10.2174/1389450117666160217123304
PubMed ID:26898309

Download

Full text not available from this repository.
View at publisher